Cyclic guanosine 3', 5'-monophosphate (cGMP) mediates a wide spectrum of physiologic
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …

Introduction 3. Discovery of NO 3.1. Nitric oxide and the Nobel prize 3.2. NO generation and
nitric oxide synthase 3.2. 1. eNOS 3.2. 2. iNOS 3.2. 3. nNOS 3.3. Nitrovasodilators 4. NO …

Pulmonary hypertension (PH) is associated with impaired production of the vasodilator nitric
oxide (NO). Riociguat (BAY 63-2521; Bayer Healthcare AG, Wuppertal, Germany) acts …

Direct stimulation of soluble guanylate cyclase (sGC) represents a promising therapeutic
strategy for the treatment of a range of diseases, including the severely disabling pulmonary …

The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …

Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …

The second messenger cyclic guanosine 3′, 5′-monophosphate (cGMP) plays a crucial
role in the control of cardiovascular and gastrointestinal homeostastis, but its effects on …

B-type natriuretic peptide (BNP) is a member of the natriuretic peptide family, a group of
widely distributed, but evolutionarily conserved, polypeptide mediators that exert myriad …

Nitric oxide (NO) functions in biology as both a critical cytotoxic agent and an essential
signaling molecule. The toxicity of the diatomic gas has long been accepted; however, it was …

Background—Cinaciguat (BAY 58–2667) is the first of a new class of soluble guanylate
cyclase activators in clinical development for acute decompensated heart failure. We aimed …